8/7/2019 compile 1-7

1/7

II. INTRODUCTION

Cervical cancer is malignant neoplasm of the cervix uteri or cervical area. It may present with

vaginal bleeding, but symptoms may be absent until the cancer is in its advanced stages.

Treatment consists of surgery, including local excision, in early stages and chemotherapy and

radiotherapy in advanced stages of the disease.

Pap smear screening can identify potentially precancerous changes. Treatment of high grade

changes can prevent the development of cancer. In developed countries, the widespread use of

cervical screening programs has reduced the incidence of invasive cervical cancer by 50% or

more.

Human Papillomavirus (HPV) infection is a necessary factor in the development of almost all

cases of cervical cancer. HPV vaccines effective against the two strains of HPV that currently

cause approximately 70% of cervical cancer have been licensed in the U.S, Canada, Australia

and the EU. Since the vaccines only cover some of the cancer causing high-risk" types of HPV,

women should seek regular Pap smear screening, even after vaccination.

Worldwide, cervical cancer is twelfth most common and the fifth most deadly cancer in women.

It affects about 16 per 100,000 women per year and kills about 9 per 100,000 per year.

Approximately 80% of cervical cancers occur in developing countries. Worldwide, in 2008, it

was estimated that there were 473,000 cases of cervical cancer, and 253,500 deaths per year.

In the United States, it is only the 8th most common cancer of women. In 1998, about 12,800

women were diagnosed in the US and about 4,800 died. In 2008 in the US an estimated 11,000

new cases were expected to be diagnosed, and about 3,870 were expected to die of cervical

cancer. Among gynecological cancers it ranks behind endometrial cancer and ovarian cancer.The incidence and mortality in the US are about half those for the rest of the world, which is due

in part to the success of screening with the Pap smear. The incidence of new cases of cervical

cancer in the United States was 7 per 100,000 women in 2004. Cervical cancer deaths decreased

by approximately 74% in the last 50 years, largely due to widespread Pap smear screening.The

annual direct medical cost of cervical cancer prevention and treatment is prior to introduction of

the HPV vaccine was estimated at $6 billion.

In the European Union, there were about 34,000 new cases per year and over 16,000 deaths due

to cervical cancer in 2004.

In the United Kingdom, the age-standardised european incidence is 8.5/100,000 per year (2006).

It is the twelfth most common cancer in women, accounting for 2% of all female cancers, and is

the second most common cancer in the under 35s females, after breast cancer. The UK's

European age-standardised mortality is 2.4/100,000 per year (2007) (Cancer Research UK

Cervical cancer statistics for the UK). With a 42% reduction from 1988-1997 the NHS

implemented screening programme has been highly successful, screening the highest risk age

group (2549 years) every 3 years, and those ages 5064 every 5 years.

In Canada, an estimated 1,300 women will be diagnosed with cervical cancer in 2008 and 380

will die.

In Australia, there were 734 cases of cervical cancer (2005). The number of women diagnosed

with cervical cancer has dropped on average by 4.5% each year since organised screening began

in 1991 (19912005). Regular two-yearly Pap tests can reduce the incidence of cervical cancer

by up to 90% in Australia, and save 1,200 Australian women dying from the disease each year.

8/7/2019 compile 1-7

2/7

During our duty in the infirmary ward in a hospital in Quirino, Manila, our group encountered a

patient with cervical cancer and were assigned to give nursing care to this patient. During her the

time she was admitted, we monitored vital signs, reminded her of her medication, followed-up

on laboratory reports and results and provided health teachings regarding her condition and

proper self care.

We observed and saw the severity of this condition in person and experienced this like never

before. We became intrigued and curious that we decided to focus our case study on this

condition. We saw it as a challenge that would help improve our ability to understand and

research on a topic that we find interesting.

II. OBJECTIVES

8/7/2019 compile 1-7

3/7

General Objective:

After conducting the case the presentation, the participants will be able to gain

knowledge about cervical carcinoma stage 2 with anemia secondary to chronic bleeding,

demonstrate adequate skills in analyzing the nursing process and appreciate the importance of

nurses role in providing appropriate management for a client having the disease.

To be able to apply what we have learned theoretically at the clinical setting and after that

study, we can be able to understand this disease deeper together with the help of our

Clinical Instructor and able to provide optimum or standard quality care to the patient through

making of the nursing intervention and health education regimen.

Specific Objectives:

Student-Nurse Centered

Describe the common characteristic of cervical cervical carcinoma stage 2 with anemia

secondary to chronic bleeding.

Present the anatomy and physiology of cervical carcinoma stage 2 with anemia secondary

to chronic bleeding related with our clients condition.

Discuss the etiology, pathophysiology and clinical manifestation of our clients condition.

Relate the significance of laboratory results to clients conditions or the disease process.

Identify the classification, indication, mechanism of action, special precautions, side

effects, dosage and availability and nursing responsibilities of the drug administered to

the client.

Discuss comprehensively nursing care plans formulated specifically based on clients

condition.

Discuss the medical and surgical interventions related to the client.

Formulate a comprehensive discharge plan realistic to the needs and compliance of the

client.

Client Centered

To manage her disease

To know the importance of her compliance to her disease

To prevent and manage the potential complication that might occur

8/7/2019 compile 1-7

4/7

Performed emphasized health teaching and following dietary instruction and restriction as

well as performing appropriate exercise

III. PATIENTS PROFILE

NAME: Ms. MS

ADDRESS: Muntalban

AGE: 48 y/o

GENDER: Female

DATE OF BIRTH: 10/10/1963PLACE OF BIRTH: Masbate

ETHNIC GROUP: Bicolana

PRIMITIVE DIALECT

SPOKEN:

Bicol, Tagalog

CIVIL STATUS: Single

EDUCATIONAL

ATTAINMENT:

College graduate

RELIGIOUS ORIENTATION: Roman Catholic

OCCUPATION Grade school teacher

HEALTH CARE FINANCING

AND USUAL SOURCE OF

MEDICAL CARE:

Money from husband

INCOME (ALLOWANCE): 14 15 thousand pesos per month

ADMITTING DIAGNOSIS Cervical carcinoma stage II-B with

anemia secondary to chronic bleedings/p chemotherapy + 3 cycles

DATE AND TIME OF

ADMISSION

February 28,2011 ; 12:41pm

TOTAL NUMBER OF DAYS

ADMITTED

3 days

ATENDING PHYSICIAN Dr. RAVIE, DELA CRUZ

8/7/2019 compile 1-7

5/7

IV. HISTORY OF PAST ILLNESS

Patient M.S. stated that she was born healthy. She was just hospitalized when she was 17yrs old at a hospital in Masbate because she had difficulty in breathing. She stayed at the hospitalfor 3 days. She was then diagnosed with Asthma. The patients asthma attacks rarely and whenshe is experiencing mild asthma attacks, she just used inhaler, but when severe asthma attacks,

the patient used nebulizer( ventolin).

The patient became pregnant 3 times. The first one was to a healthy baby boy. She gavebirth at home through hilot. The second one was aborted and the third was a healthy baby girl.She also gave birth through hilot again. She did not take any medications before and duringpregnancy

When the patient had fever, she just drinks Biogesic 3 times a day. She just self-medicates when experiencing coughs and colds.

The patient has no allergies and never experienced any accidents.

IMMUNIZATIONS:

IMMUNIZATION 1ST DOSAGE 2ND DOSAGE 3RD DOSAGE

BCG

ANTI - HEPATITIS

DPT

OPV

AMV

V. HISTORY OF PRESENT ILLNESS

Last November 2010, the patient noticed that her menstrual flow was abnormally high.The patient used 5 pads per day and all were fully soaked with blood. The patient justdisregarded it. 2 weeks prior to admission, the patient experienced 2 episodes of vaginalbleeding. She used 3 pediatric diapers which were slightly soaked. She also experienceddizziness.

1 week prior to admission, the patient was advised to go to St. Lukes Medical City for

check up. The doctor said that she has cervical problem and her hemoglobin is abnormally low.She was also advised for blood transfusion. The patient was also prescribed with TranexamicAcid and Ferrous sulfate.

The patient was admitted to Ospital ng Maynila because she has a relative working in thishospital. The patient was admitted on Feb. 28, 2011 at 12:41 pm for the complaint of vaginalbleeding

VI. FAMILY HEALTH HISTORY / GENOGRAM

8/7/2019 compile 1-7

6/7

The patients grand parents are deceased except for her grandmother on her mothers

side. Both of her parents are still alive. The patient is married and has two children, one male and

one female.

Genetic diseases in her family are asthma, diabetes and hypertension. Asthma was in the

genes of her grandmother on her fathers side of the family and was inherited by her and herfather. Diabetes came from her grandfather from her fathers side of the family but was not

passed down. Hypertension originated from her grandfather on her mothers side of the family,

passed down to her mother.

VII. OBSTETRICAL HISTORY

8/7/2019 compile 1-7

7/7

Menstrual History

At the age of 13 the patient experienced menarche. The duration of her period usually last

for 3 4 days and she usually consumes 3 pads per day. She does not experience dysmenorrheal.

Sexual History

Her first coitus was when she was 22 years old. The patient had only 1 sexual partner.

Post cervical bleeding is absent, no pain during sexual intercourse and has no sexual transmitted

disease. The patient used oral contraceptive pill on 1990 and stopped on 1993.

Obstetric Scoring

Gravida Year Gender TermType of

DeliveryLocation Weight

G1 1986 Female Full Term NSDHome by

hilotUnremarkable

G2 1987 - Abortus - - -

G3 1989 Male Full Term NSDHome by

hilotUnremarkable